drugset / Trial / NCT04672499

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

NCT04672499

Phase 1 Completed 36 enrolled Corcept Therapeutics
RandomizedSequentialDouble-blindTreatment

Summary

This study will assess the safety, tolerability, and pharmacokinetics (PK) of miricorilant (CORT118335) tablet formulations following single and multiple oral administration in healthy participants.

Timeline

Start
2020-04-27
Primary completion
2020-09-07
Completion
2020-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Miricorilant Small molecule 300 mg Oral
Subject Miricorilant Small molecule 600 mg Oral
Subject Miricorilant Small molecule 750 mg Oral
Subject Miricorilant Small molecule 900 mg Oral
Subject Miricorilant Small molecule 1350 mg Oral

Indications

No indication recorded.